## Contraceptive Treatment Selector

Charts revised December 2019. Full information available at www.hiv-druginteractions.org

For personal use only. Not for distribution.

<table>
<thead>
<tr>
<th>Progestin (Combined Oral Contraceptive, COC)</th>
<th>ATV/3TC</th>
<th>ATV/r</th>
<th>D4T/3TC</th>
<th>DDI/r</th>
<th>Efavr</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>MVC</th>
<th>BIC/FTC</th>
<th>FTC</th>
<th>EFV</th>
<th>EFV/FTC</th>
<th>ETV/FTC</th>
<th>NVP/3TC</th>
<th>RTV</th>
<th>RAL</th>
<th>ABC</th>
<th>FTC/3TC</th>
<th>FTC/FTC</th>
<th>TDF</th>
<th>ZDV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desogestrel</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Drospirenone</td>
<td>↑130%↑</td>
<td>↑</td>
<td>↑158%↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑56%↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Gestodene</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑14%↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>118%↑</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td>1</td>
<td></td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>119%↑</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Norethisterone (norethindrone)</td>
<td>↑185%↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>1</td>
<td>1</td>
<td>↑</td>
<td>1</td>
<td>1</td>
<td>1</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Norgestrel</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑85%↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Progestin (Progestin only pill, POP)

<table>
<thead>
<tr>
<th>Progestin (Non-estra)</th>
<th>ATV/3TC</th>
<th>ATV/r</th>
<th>D4T/3TC</th>
<th>DDI/r</th>
<th>Efavr</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>MVC</th>
<th>BIC/FTC</th>
<th>FTC</th>
<th>EFV</th>
<th>EFV/FTC</th>
<th>ETV/FTC</th>
<th>NVP/3TC</th>
<th>RTV</th>
<th>RAL</th>
<th>ABC</th>
<th>FTC/3TC</th>
<th>FTC/FTC</th>
<th>TDF</th>
<th>ZDV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desogestrel</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
<td>↓</td>
</tr>
<tr>
<td>Levonorgestrel</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑114%↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Norethisterone (Nor)</td>
<td>↔</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑183%↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Other</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### Other

<table>
<thead>
<tr>
<th>Progestin (EC)</th>
<th>ATV/3TC</th>
<th>ATV/r</th>
<th>D4T/3TC</th>
<th>DDI/r</th>
<th>Efavr</th>
<th>ETV</th>
<th>NVP</th>
<th>RPV</th>
<th>MVC</th>
<th>BIC/FTC</th>
<th>FTC</th>
<th>EFV</th>
<th>EFV/FTC</th>
<th>ETV/FTC</th>
<th>NVP/3TC</th>
<th>RTV</th>
<th>RAL</th>
<th>ABC</th>
<th>FTC/3TC</th>
<th>FTC/FTC</th>
<th>TDF</th>
<th>ZDV</th>
</tr>
</thead>
<tbody>
<tr>
<td>Levonorgestrel (EC)</td>
<td>↑</td>
<td></td>
<td>↑</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>↓</td>
<td>↓</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑58%↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
<td>↑</td>
</tr>
<tr>
<td>Mifepristone</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td></td>
<td>↑1</td>
<td>↑1</td>
<td></td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
</tr>
<tr>
<td>Ulipristal</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td></td>
<td>↑1</td>
<td>↑1</td>
<td></td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
<td>↑1</td>
</tr>
</tbody>
</table>

### Colour Legend

- **Green**: No clinically significant interaction expected.
- **Yellow**: These drugs should not be coadministered.
- **Orange**: Potential interaction which may require a dose adjustment or close monitoring.
- **Red**: Potential interaction predicted to be of weak intensity. No prior dosage adjustment is recommended.

### Text Legend

- **↑**: Potential increased exposure of the hormone
- **↓**: Potential decreased exposure of the hormone
- **↔**: No significant effect
- **∀**: Numbers refer to increase or decrease in AUC as observed in drug-drug interaction studies.

### Notes

- Product labels for atazanavir/cobicistat advise coadministration with hormonal contraceptives should be avoided and an alternate (non-hormonal) reliable method of contraception is recommended.
- Unboosted ATV increased ethinylestradiol AUC by 48%. Use no more than 30 µg of ethinylestradiol if coadministered with unboosted ATV and at least 35 µg of ethinylestradiol if coadministered with ATV.
- Alternative or additional contraceptive measures are recommended.
- Depending on the contraceptive method, ethinylestradiol can be either unchanged (COC) or decreased (CVR). Levels of coadministered progestin were markedly decreased. A reliable method of barrier contraception must be used in addition to oral contraception.
- European SPC states a hormonal contraceptive should contain at least 30 µg ethinylestradiol.
- Increased conversion to the active metabolite, etonogestrel.
- When used in a COC the ethinoge component is reduced. In the absence of clinical data on the contraceptive efficacy, caution is recommended and additional contraceptive measures should be used.
- A reliable method of barrier contraception must be used in addition to oral contraception.
- When used in a COC, the estrogen component is reduced to a limited extent. The European SPC states a hormonal contraceptive should contain at least 30 µg ethinylestradiol.
- Coadministration is contraindicated in the US product label due to the potential for hyperkaemia. The European product label recommends clinical monitoring for hyperkalaemia.
- Unboosted ATV increased norethisterone AUC by 2.1-fold.
- The use of implants or vaginal rings is not recommended in women on long-term treatment with hepatic enzyme-inducing drugs.
- Predicted to increase etonogestrel but to reduce ethinylestradiol concentrations. Since no dosage adjustment of ethinylestradiol is possible with the CVR, alternative forms of contraception should be used.
- The efficacy of norelgestromin patch is unlikely to be impaired since the patch releases 33 µg ethinylestradiol/day which meets the recommendation in the product labels for atazanavir that the hormonal contraceptive should contain at least 30 µg ethinylestradiol in presence of atazanavir/ritonavir.
- Norelgestromin is administered with ethinylestradiol as a transdermal patch. Ethinylestradiol exposure was reduced which may compromise contraceptive efficacy. Caution is recommended and additional contraceptive measures should be used.
- Any increase in exposure is unlikely to be clinically significant when used as a single dose.
- Use 3 mg as a single dose for emergency contraception. Of note, the doubling of the standard dose is outside the product license and there is limited evidence in relation to efficacy.
- Non-hormonal emergency contraception (Cu-IUD) should be considered.

---

**Abbreviations**

- ATV: atazanavir
- DDI: dolutegravir
- DRTV: dolutegravir and ritonavir
- DRV: darunavir
- EFV: efavirenz
- ETV: etravirine
- FTC: emtricitabine
- FTDF: emtricitabine and tenofovir
- FTC/3TC: emtricitabine and lamivudine
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC: emtricitabine
- FTC/3TC: emtricitabine and lamivudine
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofovir
- FTC/FTC: emtricitabine and tenofover